REG - One Health Group PLC - Trading Update

One HealthAnnouncement

10/02/2026 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260210:nRSJ3032Sa&default-theme=true

RNS Number : 3032S  One Health Group PLC  10 February 2026

 

One Health Group plc

("One Health", the "Company" or the "Group")

 

Trading Update

 

H2 trading remains strong with outlook unchanged

FY 26 Revenue and EBITDA growth remains in-line with expectations

Continued strong growth across all KPIs

 

One Health Group plc (AIM: OHGR), the independent provider of NHS-funded
surgical procedures for patients referred from the NHS through 'Patient
Choice', confirms that second half trading remains strong and the business is
on track to deliver growth at the revenue and underlying EBITDA levels for the
year ending 31 March 2026 (FY26) in-line with market expectations(1), and at
the higher end of the consensus revenue range. FY26 trading will show
continued growth across all operational and financial key performance
indicators.

 

(1)Management understands consensus market forecasts for revenue to range from
£29.2m to £29.6m with underlying EBITDA for FY26 of £2.3m across consensus.

 

Update on first new-build surgical hub

The Company has received guidance that the final pre-commencement planning
condition sign-off, relating to environmental matters, is expected to be
confirmed within the coming weeks, with the remaining six pre-commencement
conditions having already been satisfied. The Board remains confident that,
once all planning condition signoffs are in place, the project will proceed in
line with the anticipated one-year construction timetable, with contractors
ready to start immediately. On completion, the new surgical hub is expected to
provide significant additional surgical operating capacity and has the
potential to materially enhance the Group's revenue and profitability.

 

Outlook

The Company has seen no change in trading performance towards the end of the
financial year and remains well funded to deliver continued organic growth and
execute the roll-out of the first surgical hub, accelerating growth and
improving profitability. The Board is confident that the business will
continue to deliver organic growth through increased new patient referrals, a
strong pipeline of new surgeons, and additional surgical capacity in existing
and new independent sector hospitals to help deliver on challenging Government
Waiting List reduction targets.

 

Adam Binns, Chief Executive Officer, commented:

"We are delighted that our growth plans remain unaffected by wider concerns of
reductions in elective surgery across England, and that we are in a strong
position to continue to support the NHS in their aim to reduce national
waiting lists from the current 7.3 million level.

 

"We work very effectively with multiple NHS commissioning bodies across a wide
geography in addition to contracts directly with local NHS hospitals to
support the reduction of internal 'long waits'. In any case, the vast majority
of our activity is from brand new patients referred by their GP directly to
One Health by exercising their legal right to choose their provider of care
through 'patient choice'. We have seen increasing year on year demand in
direct GP referrals as more and more new patients enter the system looking for
treatment. As well as increased GP referrals, and as anticipated, we have also
seen an increase in NHS hospital referrals in H2 supported by additional
funding from the NHS 'quarter four sprint' initiative, where local NHS
hospitals transfer NHS patients from their internal patient waiting lists."

 

"We are very proud to be a trusted provider of support to the NHS for over 21
years, with excellent long-standing relationships, and we continue to look
forward to the future with confidence, providing much needed care, free at the
point of delivery for NHS patients, across an ever-increasing geography, and
reducing pressure on the NHS."

 

If you wish to keep up to date on Company news please email:
onehealth@walbrookpr.com (mailto:onehealth@walbrookpr.com)

For more information, please contact:

 

 One Health Group plc                                                                                                www.onehealth.co.uk/investors (http://www.onehealth.co.uk/investors)

 Derek Bickerstaff, Chairman                                                                                         Via Walbrook PR

 Adam Binns, CEO

 Panmure Liberum (Nominated Adviser and Broker)                                                                      Tel: +44 (0)20 3100 2000

 Emma Earl, Will Goode, Mark Rogers

 Rupert Dearden

 Walbrook PR (Media & Investor Relations)      Tel: +44 (0)20 7933 8780 or onehealth@walbrookpr.com

                                             (mailto:onehealth@walbrookpr.com)
 Alice Woodings / Paul McManus /

                                             Mob: +44 (0)7407 804 654 / +44 (0)7980 541 893 /
 Rachel Broad

                                               +44 (0)7747 515 393

 

About One Health Group plc (www.onehealth.co.uk (http://www.onehealth.co.uk) )

One Health engages 80 NHS Consultants (excluding anaesthetists) who
sub-specialise in the various surgeries offered by the Company, through a
growing network of community-based outreach clinics and surgical operating
locations. One Health continues to deliver strong growth and, in the year, to
March 2025 provided much needed care to 17,020 new patients, through over
42,000 consultations and over 7,000 surgical procedures. One Health deploys
surgeons and anaesthetists that are mostly employed by the NHS, on a
subcontracted basis. It currently works with over 100 professionals across 9
independent hospitals and 37 outreach clinics. Within these community-based
outreach clinics all consultations and post operative physiotherapy is
delivered where required, reducing patient inconvenience and excess travel.

 

One Health's activities are focused on areas where NHS patient needs are
under-supplied by the local NHS service, population density is relatively high
and the level of private medical insurance or the ability to self-fund is
relatively low. Currently, the Company's activities are focused in Yorkshire,
Lincolnshire, Derbyshire, Nottinghamshire and Leicestershire. Revenue is
derived from over 60 NHS commissioning bodies in addition to contracts with
local NHS Hospital Trusts to transfer their internal waiting list patients to
One Health for quicker treatment.

 

One Health's business model has focused to date on four main areas:
orthopaedics, spine, general surgery and gynaecology, with urology introduced
at the end of FY25.

 

Spine and orthopaedics are particularly attractive areas for One Health as the
Directors believe that they benefit from powerful growth drivers in terms of
an ageing demographic, physical inactivity and an increasing proportion of the
population being categorised as obese. Within orthopaedics, the most common
surgeries performed by One Health are knee and hip replacements.

 

Online investor presentation

Click below for the latest online presentation by Derek Bickerstaff, Chairman
and Adam Binns, Chief Executive Officer, which offers insights into the
Company's growth strategy and long-term vision:

https://sparklive.lseg.com/ONEHEALTHGROUP/events/3c988809-19ad-454c-af31-cfe86bfe7da5/one-health-group-half-year-results-announcement
(https://sparklive.lseg.com/ONEHEALTHGROUP/events/3c988809-19ad-454c-af31-cfe86bfe7da5/one-health-group-half-year-results-announcement)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TSTFLFFRFAIAIIR



            Copyright 2019 Regulatory News Service, all rights reserved